Capricor Therapeutics Faces Securities Class Action Over Clinical Data

The legal action centers on allegations that Capricor violated the Securities Exchange Act of 1934 by providing false information to the market. According to the complaint, the company altered the statistical analysis plan for clinical data related to Deramiocel without securing prior FDA agreement. This omission allegedly concealed significant risks that the drug’s Biologics License Application would be rejected due to insufficient evidence of effectiveness.

Shareholders seeking to act as lead plaintiffs have until September 28, 2026, to file their requests. While the class has not yet been certified, attorneys Brian Schall and David Schwartz are inviting affected investors to discuss potential recovery options. The firm emphasizes that participation in the suit is not a requirement for individual investors to seek a recovery should the litigation prove successful.